AVEO Oncology to Host Conference Call and Webcast to Review Phase 3 TIVO-1 Data Presented at ASCO

Press Release

View printer-friendly version

<<  Back

AVEO Oncology to Host Conference Call and Webcast to Review Phase 3 TIVO-1 Data Presented at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 30, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO-1 data that will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). The call can be accessed by dialing 1-800-215-2410 (domestic) or 1-617-597-5410 (international) five minutes prior to the start of the call and providing the passcode 59157252. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 77088629.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the AVEO website at www.investor.aveooncology.com. A replay of the webcast will be archived on the company’s website for two weeks following the call.

About AVEO

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. AVEO's proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company's website at www.aveooncology.com.

Source: AVEO Oncology

AVEO Oncology
Investor Contact:
Monique Allaire, 617-299-5810
or
Media Contact:
Rob Kloppenburg, 617-930-5595